CI

At a glance

ClinicalIndex Comparison Record
Phase 4Completed· 5,530 enrolled
Drug / intervention
Clopidogrel +1 moredrug
Likely dose
Clopidogrel 75mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT02044250
NCT02044250Phase 4Completed

Comparison of Clopidogrel vs. Aspirin Monotherapy Beyond Two Year After Drug-eluting Stent Implantation

Seoul National University Hospital·interventional·Posted Jan 23, 2014·Updated Apr 27, 2026

In Brief

A Phase 4 clinical trial evaluating Clopidogrel and Aspirin for Coronary Heart Disease. Completed, enrolled 5,530 participants across 1 site.

Detailed Summary

Objectives : To compare the efficacy and safety of clopidogrel monotherapy with aspirin monotherapy in patients who received dual or triple antiplatelet therapy for 1 year (± 6 months) after drug-eluting stent implantation for coronary artery disease Patient Enrollment : 5530 patients enrolled at 55 centers in Korea Patient Follow-up : Clinical follow-up will occur at 1, 12 and 24 months. Primary Endpoint : Composite endpoint of MACE and major bleeding Secondary Endpoint : Device-oriented composite outcome including TLR (target lesion revascularization), TVR (target vessel revascularization), stent thrombosis, and minor GI (gastrointestinal) complications

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
CountriesSouth Korea

Timeline

Phase 4CompletedFinished
2014201520162017201820192020202120222023202420252026
First PostedJan 23, 2014
Enrollment StartFeb 1, 2014
Primary CompletionMar 1, 2021
Study CompletionOct 1, 2025
TodayJul 2, 2026
Enrollment to primary: 7.1 yearsPosted 12.4 years ago

Interventions

Clopidogreldrug

Clopidogrel 75mg 1tab P.O. daily

Aspirindrug

Aspirin 100\~200mg 1\~2tab P.O. daily